Temozolomide Teva

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

temozolomide

Disponible depuis:

Teva B.V. 

Code ATC:

L01AX03

DCI (Dénomination commune internationale):

temozolomide

Groupe thérapeutique:

Antineoplastic agents

Domaine thérapeutique:

Glioma; Glioblastoma

indications thérapeutiques:

For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Descriptif du produit:

Revision: 21

Statut de autorisation:

Authorised

Date de l'autorisation:

2010-01-28

Notice patient

                                47
B. PACKAGE LEAFLET
48
PACKAGE LEAFLET: INFORMATION FOR THE USER
TEMOZOLOMIDE TEVA 5 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 20 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 100 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 140 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 180 MG HARD CAPSULES
TEMOZOLOMIDE TEVA 250 MG HARD CAPSULES
temozolomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Temozolomide Teva is and what it is used for
2.
What you need to know before you take Temozolomide Teva
3.
How to take Temozolomide Teva
4.
Possible side effects
5.
How to store Temozolomide Teva
6.
Contents of the pack and other information
1.
WHAT TEMOZOLOMIDE TEVA IS AND WHAT IT IS USED FOR
Temozolomide Teva contains a medicine called temozolomide. This
medicine is an antitumour agent.
Temozolomide Teva is used for the treatment of specific forms of brain
tumours:
-
in adults with newly-diagnosed glioblastoma multiforme. Temozolomide
Teva is first used
together with radiotherapy (concomitant phase of treatment) and after
that alone (monotherapy
phase of treatment).
-
in children 3 years and older and adult patients with malignant
glioma, such as glioblastoma
multiforme or anaplastic astrocytoma. Temozolomide Teva is used in
these tumours if they
return or get worse after standard treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TEMOZOLOMIDE TEVA
DO NOT TAKE TEMOZOLOMIDE TEVA
-
if you are allergic to temozolomide or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have had an allergic reaction to
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Temozolomide Teva 5 mg hard capsules
Temozolomide Teva 20 mg hard capsules
Temozolomide Teva 100 mg hard capsules
Temozolomide Teva 140 mg hard capsules
Temozolomide Teva 180 mg hard capsules
Temozolomide Teva 250 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Temozolomide Teva 5 mg hard capsules
Each hard capsule contains 5 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 87 mg of lactose.
Temozolomide Teva 20 mg hard capsules
Each hard capsule contains 20 mg temozolomide.
_Excipients with known effect _
Each hard capsule contains 72 mg of lactose and sunset yellow FCF
(E110).
Temozolomide Teva 100 mg hard capsules
Each hard capsule contains 100 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 84 mg of lactose.
Temozolomide Teva 140 mg hard capsules
Each hard capsule contains 140 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 117 mg of lactose.
Temozolomide Teva 180 mg hard capsules
Each hard capsule contains 180 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 150 mg of lactose.
Temozolomide Teva 250 mg hard capsules
Each hard capsule contains 250 mg temozolomide.
_Excipient with known effect _
Each hard capsule contains 209 mg of lactose.
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Hard capsule.
Temozolomide Teva 5 mg hard capsules
The hard capsules have a white opaque body and cap with two stripes in
green ink on the cap and with
“T 5 mg” in green ink on the body. Each capsule is approximately
16 mm in length.
Temozolomide Teva 20 mg hard capsules
The hard capsules have a white opaque body and cap with two stripes in
orange ink on the cap and
with “T 20 mg” in orange ink on the body. Each capsule is
approximately 18 mm in length.
Temozolomide Teva 100 mg hard capsules
The hard capsules have a white opaque body and cap with two stripes in
pink ink on the cap and with
“T 100
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation bulgare 18-09-2014
Notice patient Notice patient espagnol 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation espagnol 18-09-2014
Notice patient Notice patient tchèque 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation tchèque 18-09-2014
Notice patient Notice patient danois 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation danois 18-09-2014
Notice patient Notice patient allemand 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation allemand 18-09-2014
Notice patient Notice patient estonien 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation estonien 18-09-2014
Notice patient Notice patient grec 18-02-2022
Notice patient Notice patient français 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation français 18-09-2014
Notice patient Notice patient italien 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation italien 18-09-2014
Notice patient Notice patient letton 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation letton 18-09-2014
Notice patient Notice patient lituanien 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation lituanien 18-09-2014
Notice patient Notice patient hongrois 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation hongrois 18-09-2014
Notice patient Notice patient maltais 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation maltais 18-09-2014
Notice patient Notice patient néerlandais 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation néerlandais 18-09-2014
Notice patient Notice patient polonais 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation polonais 18-09-2014
Notice patient Notice patient portugais 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation portugais 18-09-2014
Notice patient Notice patient roumain 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation roumain 18-09-2014
Notice patient Notice patient slovaque 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation slovaque 18-09-2014
Notice patient Notice patient slovène 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation slovène 18-09-2014
Notice patient Notice patient finnois 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation finnois 18-09-2014
Notice patient Notice patient suédois 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation suédois 18-09-2014
Notice patient Notice patient norvégien 18-02-2022
Notice patient Notice patient islandais 18-02-2022
Notice patient Notice patient croate 18-02-2022
Rapport public d'évaluation Rapport public d'évaluation croate 18-09-2014

Rechercher des alertes liées à ce produit

Afficher l'historique des documents